	Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141]. Eur Urol Open Sci Bickley L, Fransen van de Putte EE, van den Brink L, Marandino L, van der Mijn JC, Wilgenhof S, van Thienen JV, Haanen JBAG, Boleti E, Powles T, Zondervan PJ, Graafland NM, Tippu Z, Turajlic S, Bex A. PMID: 42305796 [PubMed]
	Combining the PI-RADS v2.1 score with PSAD improves the diagnostic accuracy of transition zone prostate cancer. Arch Med Sci Zhong J, Ding J, Zhang Y, Yang Q. PMID: 42305309 [PubMed]
	First-in-human evaluation of [(18)F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-617. Ann Med He J, Wang Y, Tang W, Gao X, Cai Y, Tang Y, Hu S. PMID: 42304982 [PubMed - indexed for MEDLINE]
	Editorial Comment on to Investigate Disparities in Strategies for Low-Risk Prostate Cancer by Facility Type Using the Japan Study Group of Prostate Cancer Database. Int J Urol Tohi Y, Merseburger AS, Sugimoto M. PMID: 42304637 [PubMed - in process]
	Kidney cancer burden in China from 1990 to 2023: A retrospective population-based observational study. J Int Med Res Bai Z, Wang S, Wang H, Wang Y, Huang G, Hou Y. PMID: 42304621 [PubMed - indexed for MEDLINE]
	Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line, Immune-Based Combinations. Cancer Rep (Hoboken) Sakurai H, Shiga M, Kandori S, Takahashi S, Omiya A, Ishida T, Matsuda K, Isoda B, Mathis BJ, Komine M, Iinuma M, Joraku A, Negoro H, Tsutsumi M, Inoue T, Miyazaki J, Nishiyama H. PMID: 42304594 [PubMed - indexed for MEDLINE]
	Incidence and Risk Factors of Postoperative Acute Kidney Injury in Colorectal Cancer Patients With Metabolic Syndrome: A Retrospective Cohort Study. Ann Ital Chir Zha Q, Xiong K, Wei M, Chen Y. PMID: 42304146 [PubMed - indexed for MEDLINE]
	Navigating work after prostate cancer treatment: a systematic review of qualitative research. J Cancer Surviv Tomic D, Keegel T, Schellack SK, Abdel-Malek L, Jander C, Hettige ST, MacFarlane E, Millar J, Walker-Bone K. PMID: 42303926 [PubMed - as supplied by publisher]
	A preoperative Artificial Intelligence model to estimate cancer-specific mortality in nonmetastatic kidney cancer patients. Nat Commun Larcher A, Traverso A, Scuri P, Capitanio U, Musso G, Canibus D, Barbieri S, Caivano L, Zambello A, Denti M, Campi R, Serni S, Granata S, Palmisano A, Vignale D, Montorsi F, Esposito A, Tacchetti C, Salonia A. PMID: 42303642 [PubMed - as supplied by publisher]
	Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo. Clin Genitourin Cancer McNeel DG, Eickhoff JC, Perez A, Liu G. PMID: 42303538 [PubMed - as supplied by publisher]
	Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer. Eur Urol Francini E. PMID: 42303526 [PubMed - as supplied by publisher]
	Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study. Eur Urol Mertens LS, Mellema JJ, Sridhar S, van der Heijden MS. PMID: 42303524 [PubMed - as supplied by publisher]
	Re: Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial. Eur Urol Ma H, Zhou Q. PMID: 42303523 [PubMed - as supplied by publisher]
	Re: Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial. Eur Urol Yusuf S, Azam A, Sood I, Al-Sattar H, Mullassery V, Adeleke S. PMID: 42303522 [PubMed - as supplied by publisher]
	Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials. Eur Urol Oncol Light A, Peters M, Gopalakrishnan A, Mayor N, Freeman A, Emberton M, Ahmed HU, Shah TT. PMID: 42303478 [PubMed - as supplied by publisher]
	Prevalence of homologous recombination repair genes alterations in metastatic castration-resistant prostate cancer, a multicentric study. Fr J Urol Allaume P, Raby M, Nourieh M, Lespagnol A, Tallet A, Péricart S, Tantot J, Lindner V, Decaussin M, Callens C, Descotes F, Allory Y, Rioux-Leclercq N, Kammerer-Jacquet SF, Fromont G. PMID: 42303208 [PubMed - as supplied by publisher]
	Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer. J Natl Compr Canc Netw Scilipoti P, de Angelis M, Thibault C, , Del Giudice F, Contieri R, Hurle R, Subiela JD, Simone G, Proietti F, Mori K, Shariat S, D'Andrea D, Zamboni S, Suardi N, Tanaka H, Matsumoto S, Fujii Y, Bertolo R, Antonelli A, Diamant E, Vordos D, Gabriel PE, Harber T, Colombel M, Hanquiez P, Chatain V, Duquesne I, Borz MB, Verhoest G, Mauger De Varennes A, Surlemont L, Ghenassia M, Masson-Lecomte A, Peyrottes A, Lebacle C, Beniac P, Léon P, Larré S, Taha F, Marcq G, Szostek A, Pradere B, Calleris G, Audenet F, Xylinas E, Allory Y, Bajeot AS, Prost D, Grobet-Jeandin E, Montorsi F, Necchi A, Briganti A, Moschini M, Roumiguié M, Rouprêt M, Seisen T. PMID: 42302838 [PubMed - as supplied by publisher]
	Hepatic Inflammatory Pseudotumor Presenting as FDG-avid Liver Lesions in a Prostate Cancer Patient: A Diagnostic Pitfall on PET/CT. Clin Nucl Med Weng Y, Yin H, Shi H. PMID: 42302736 [PubMed - as supplied by publisher]
	Multiplex biomarker detection platform based on zinc protoporphyrin-modified gold electrodes: Application potential for early diagnosis and postoperative monitoring of prostate cancer. Biosens Bioelectron Lin HY, Liao CC, Tsai SH, Yu KJ, Hua MY. PMID: 42302329 [PubMed - as supplied by publisher]
	Machine-learning-assisted artificial olfactory colorimetric sensor array for bladder cancer early detection from urinary volatile organic compounds. Biosens Bioelectron Xiong Y, Xiao J, Jing L, Bian Y, Liao L, Hou Z, Xia GJ, Yu A, Niu Y. PMID: 42302328 [PubMed - as supplied by publisher]

Articles 1 - 20 / 179062

Page 1 of 8954



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy